.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,748,438

« Back to Dashboard

Details for Patent: 8,748,438

Title:Inhibitors of Bruton's tyrosine kinase
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk, such as those having the structure of Formula (A) ##STR00001## Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Filing Date:Dec 29, 2011
Application Number:13/340,409
Claims:1. A method for treating Sjogren's syndrome comprising administering to an individual in need thereof an irreversible inhibitor of Bruton's tyrosine kinase (Btk), wherein the irreversible inhibitor is a compound having the structure of Formula (A) ##STR00058## wherein: A is N; R.sub.1 is L.sub.2-(substituted or unsubstituted heteroaryl), or L.sub.2-(substituted or unsubstituted aryl), where L.sub.2 is a bond, O, S, --S(.dbd.O), --S(.dbd.O).sub.2, C(.dbd.O), -(substituted or unsubstituted C.sub.1-C.sub.6 alkylene), or -(substituted or unsubstituted C.sub.2-C.sub.6 alkenylene); R.sub.2 and R.sub.3 are independently selected from H or lower alkyl; R.sub.4 is L.sub.3-X-L.sub.4-G, wherein, L.sub.3 is optional, and when present is an optionally substituted or unsubstituted alkylene, optionally substituted or unsubstituted cycloalkylene, optionally substituted or unsubstituted alkenylene, or optionally substituted or unsubstituted alkynylene; X is optional, and when present is O, --C(.dbd.O), S, --S(.dbd.O), --S(.dbd.O).sub.2, --NH, --NR.sub.9, --NHC(O), --C(O)NH, --NR.sub.9C(O), --C(O)NR.sub.9, --S(.dbd.O).sub.2NH, --NHS(.dbd.O).sub.2, --S(.dbd.O).sub.2NR.sub.9--, --NR.sub.9S(.dbd.O).sub.2, --OC(O)NH--, --NHC(O)O--, --OC(O)NR.sub.9--, --NR.sub.9C(O)O--, --CH=NO--, --ON.dbd.CH--, --NR.sub.10C(O)NR.sub.10--, heteroarylene, arylene, --NR.sub.10C(.dbd.NR.sub.11)NR.sub.10--, --NR.sub.10C(.dbd.NR.sub.11)--, --C(.dbd.NR.sub.11)NR.sub.10--, --OC(.dbd.NR.sub.11)--, or --C (.dbd.NR.sub.11)O--; L.sub.4 is optional, and when present is a substituted or unsubstituted alkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or substituted or unsubstituted heterocyclene; or L.sub.3, X and L.sub.4 taken together form a nitrogen containing heterocyclic ring; G is ##STR00059## wherein, R.sub.6, R.sub.7 and R.sub.8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; R.sub.9 is selected from among H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl; each R.sub.10 is independently H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower cycloalkyl; or two R.sub.10 groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or R.sub.10 and R.sub.11 can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; and R.sub.11 is selected from H, --S(.dbd.O).sub.2R.sub.8, --S(.dbd.O).sub.2NH.sub.2, --C(O)R.sub.8, --CN, --NO.sub.2, heteroaryl, or heteroalkyl; or a pharmaceutically acceptable solvate, hydrate, or salts thereof.

2. The method of claim 1, wherein the inhibitor of Btk is a selective, irreversible inhibitor of Btk.

3. The method of claim 1, wherein the inhibitor of Btk forms a covalent bond with a Bruton's tyrosine kinase (Btk).

4. The method of claim 3, wherein the covalent bond is formed from a functional group on the inhibitor of Btk and the functional group is capable of covalently binding a cysteine residue of a Bruton's tyrosine kinase (Btk).

5. The method of claim 4, wherein the cysteine residue of a Bruton's tyrosine kinase is Cys 481.

6. The method of claim 1, wherein the inhibitor of Btk forms a covalent bond with an amino acid residue of a Bruton's tyrosine kinase (Btk).

7. The method of claim 1, wherein the inhibitor of Btk forms a covalent bond with a cysteine residue of a Bruton's tyrosine kinase (Btk).

8. The method of claim 1, wherein the inhibitor of Btk forms a covalent bond with a cysteine 481 residue of a Bruton's tyrosine kinase (Btk).

9. The method of claim 1, wherein the inhibitor of Btk selectively binds to a Bruton's tyrosine kinase.

10. The method of claim 1, wherein the inhibitor of Btk has an IC.sub.50 of less than 1 .mu.M.

11. The method of claim 1, wherein the inhibitor of Btk has an IC.sub.50 of less than 0.25 .mu.M.

12. The method of claim 1, wherein the inhibitor of Btk is administered orally.

13. The method of claim 1, wherein the inhibitor has the structure of Formula (I): ##STR00060## wherein: L.sub.a is CH.sub.2, O, NH or S; Ar is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; Y is an optionally substituted group selected from among alkylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, and heteroarylene; Z is C(.dbd.O), OC(.dbd.O), NHC(.dbd.O), C(.dbd.S), S(.dbd.O).sub.x, OS(.dbd.O).sub.x, or NHS(.dbd.O).sub.x, where x is 1 or 2; R.sub.6 and R.sub.8 are H and R.sub.7 is optionally substituted C.sub.1-C.sub.4heteroalkyl, or optionally substituted C.sub.2-C.sub.6heterocycloalkyl; or R.sub.7 and R.sub.8 are H and R.sub.6 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkyl, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.6alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl); or R.sub.7 and R.sub.8 are substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, or substituted or unsubstituted C.sub.2-C.sub.6heterocycloalkyl, and R.sub.6 is H, substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkyl, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.6alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl); or R.sub.7 and R.sub.8 taken together form a bond and R.sub.6 is optionally substituted C.sub.1-C.sub.4heteroalkyl, or optionally substituted C.sub.2-C.sub.6heterocycloalkyl; or a pharmaceutically acceptable solvate, pharmaceutically acceptable hydrate, or pharmaceutically acceptable salt thereof.

14. The method of claim 1 wherein R.sub.2 and R.sub.3 are each independently H.

15. The method of claim 1 wherein R.sub.1 is a substituted phenyl.

16. The method of claim 1 wherein R.sub.4 is L.sub.3-X-L.sub.4-G wherein L.sub.3, X and L.sub.4 taken together form a nitrogen containing heterocyclic ring.

17. The method of claim 1 wherein G is ##STR00061##

18. The method of claim 1 wherein R.sub.6, R.sub.7, and R.sub.8 are each independently H.

19. The method of claim 1 wherein the compound has the structure ##STR00062## or a pharmaceutically acceptable solvate, hydrate, or salt thereof.

20. A method for treating Sjogren's syndrome comprising administering to an individual in need thereof an irreversible inhibitor of Bruton's tyrosine kinase (Btk), wherein the irreversible inhibitor is a compound having the structure of ##STR00063## or a pharmaceutically acceptable solvate, hydrate, or salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc